FDA takes first step in possible reversal of ban on some peptides The Washington Post FDA Issues Warning: Compounding Certain Bulk Drug Substances May Pose Major Legal and Patient Safety Risks Lengea FDA Warning Letter Breakdown: Sterility Failures, Subpotent GLP 1 Drugs, and a Compounding Pharmacy Operating Without Control The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide